Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2900133rdf:typepubmed:Citationlld:pubmed
pubmed-article:2900133lifeskim:mentionsumls-concept:C0025646lld:lifeskim
pubmed-article:2900133lifeskim:mentionsumls-concept:C0392360lld:lifeskim
pubmed-article:2900133lifeskim:mentionsumls-concept:C0870956lld:lifeskim
pubmed-article:2900133lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:2900133pubmed:issue3lld:pubmed
pubmed-article:2900133pubmed:dateCreated1988-9-15lld:pubmed
pubmed-article:2900133pubmed:abstractTextStudies conducted by Italian and Anglo-saxon authors underline the thymoanaleptic properties of a transmethylant biological substance, the S-adenosyl methionine (SAMe). The authors discuss a review of literature concerning the use of SAMe in neuro-psychiatry, particularly in the treatment of affective disorders. The many physiopathological implications are subtended by the biological inter-relations of SAMe with other biological substances. Some hypotheses are proposed on the role played by phospholipid methylation, the folate metabolism and the purinergic transmission in mental diseases.lld:pubmed
pubmed-article:2900133pubmed:languagefrelld:pubmed
pubmed-article:2900133pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2900133pubmed:citationSubsetIMlld:pubmed
pubmed-article:2900133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2900133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2900133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2900133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2900133pubmed:statusMEDLINElld:pubmed
pubmed-article:2900133pubmed:issn0013-7006lld:pubmed
pubmed-article:2900133pubmed:authorpubmed-author:AzorinJ MJMlld:pubmed
pubmed-article:2900133pubmed:authorpubmed-author:TramoniA VAVlld:pubmed
pubmed-article:2900133pubmed:issnTypePrintlld:pubmed
pubmed-article:2900133pubmed:volume14lld:pubmed
pubmed-article:2900133pubmed:ownerNLMlld:pubmed
pubmed-article:2900133pubmed:authorsCompleteYlld:pubmed
pubmed-article:2900133pubmed:pagination113-8lld:pubmed
pubmed-article:2900133pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2900133pubmed:meshHeadingpubmed-meshheading:2900133-...lld:pubmed
pubmed-article:2900133pubmed:meshHeadingpubmed-meshheading:2900133-...lld:pubmed
pubmed-article:2900133pubmed:meshHeadingpubmed-meshheading:2900133-...lld:pubmed
pubmed-article:2900133pubmed:meshHeadingpubmed-meshheading:2900133-...lld:pubmed
pubmed-article:2900133pubmed:meshHeadingpubmed-meshheading:2900133-...lld:pubmed
pubmed-article:2900133pubmed:meshHeadingpubmed-meshheading:2900133-...lld:pubmed
pubmed-article:2900133pubmed:meshHeadingpubmed-meshheading:2900133-...lld:pubmed
pubmed-article:2900133pubmed:meshHeadingpubmed-meshheading:2900133-...lld:pubmed
pubmed-article:2900133pubmed:articleTitle[Therapeutic indications of S-adenosyl methionine in neuropsychiatry].lld:pubmed
pubmed-article:2900133pubmed:affiliationClinique de Psychiatrie et de Psychologie Médicale, C.H.U. Timone, Marseille.lld:pubmed
pubmed-article:2900133pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2900133pubmed:publicationTypeEnglish Abstractlld:pubmed